Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

Impact · against what's priced in

CorMedix faces a negative outlook as 2026 revenue guidance suggests a 20-25% decline from 2025 levels due to pricing pressures on DefenCath. While the acquisition of Melinta and long-term patent protection provide a floor, the immediate trajectory indicates a loss of pricing power.

CRMD−0.50

No priced-in read yet

In context

The projection of 2026 revenues between $300-$320 million—a significant drop from 2025's ~$400 million—signals a growth deceleration and a loss of pricing power for DefenCath.

Read from the article alone

• m and a
• revenue growth
• healthcare
• biotech
• pharmaceuticals
• CRMD
• fda approval
• medical devices

Search tags